One year follow-up of the ESSENCE trial (enoxaparin versus heparin in unstable angina and non-Q-wave myocardial infarction)

Cohen, Mauricio; Bigonzi, Fredérique; Louer, Veronique Le; Gosset, F; Fromell, Gregg; Goodman, Shaun

doi:10.1016/s0735-1097(98)80988-1

Cited by 6 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An increasing number of patients with unstable angina are treated with lowmolecular-weight heparin (LMWH) prior to coronary angioplasty. 97 Because of the difficulty monitoring anticoagulation levels using LMWH during coronary angioplasty, conventional dosages of unfractionated heparin also are recommended. In this setting, conventional monitoring methods, such as the ACT, may underestimate the true degree of periprocedural anticoagulation.…”

Section: Low-molecular-weight Heparinmentioning

confidence: 99%

Antithrombotic Therapy in Patients Undergoing Percutaneous Coronary Intervention

Popma¹,

Ohman²,

Weitz³

et al. 2001

Chest

View full text Add to dashboard Cite

Section: Low-molecular-weight Heparinmentioning

confidence: 99%

Antithrombotic Therapy in Patients Undergoing Percutaneous Coronary Intervention

Popma¹,

Ohman²,

Weitz³

et al. 2001

Chest

View full text Add to dashboard Cite

“…A trend toward reduced frequency of the composite double end point of death or myocardial infarction with enoxaparin also was observed at 12 months (11.5% vs 13.5%, p=0.082). 18 Although not an end point of the study, rates of revascularization were compared between groups. The need for revascularization was subjectively determined by the physician, but it is interesting to note that patients receiving enoxaparin had significantly fewer revascularizations (27.0% vs 32.2%, p<0.01).…”

Section: Enoxaparinmentioning

confidence: 99%

Clinical Trials of Low‐Molecular‐Weight Heparins in Cardiology

Spinler

1999

Pharmacotherapy

View full text Add to dashboard Cite

Our understanding of the pathophysiology of acute coronary syndromes is evolving as the role of prognostic coagulation markers and the different effects unfractionated heparin and low-molecular-weight heparins have on these coagulation markers are investigated. The results of recent clinical trials of low-molecular-weight heparins in acute coronary syndromes are summarized, and an economic evaluation of enoxaparin for these indications is reviewed.

show abstract

Unstable angina and non-ST-segment elevation myocardial infarction

Ambrose

Tai

2002

Curr Treat Options Cardio Med

View full text Add to dashboard Cite

In the last 20 years there have been enormous advances in our understanding of the acute coronary syndromes and how to manage patients presenting with them. In the 1980s, we began to understand the importance of thrombus formation was in the pathophysiology of acute coronary syndromes. Randomized studies also showed that appropriate antithrombotic therapy reduced the subsequent occurrence of myocardial infarction and death. In the 1990s, other therapeutic modalities and particularly percutaneous coronary intervention have come to the forefront as effective therapy in these syndromes. The glycoprotein IIb/IIIa receptor antagonists along with coronary stent implantation have proved extremely beneficial in short- and long-term management. We also have learned the importance of risk-factor modification in preventing subsequent events. In the future, greater efforts will focus on primary prevention.

show abstract

One year follow-up of the ESSENCE trial (enoxaparin versus heparin in unstable angina and non-Q-wave myocardial infarction)

Cited by 6 publications

References 0 publications

Antithrombotic Therapy in Patients Undergoing Percutaneous Coronary Intervention

Antithrombotic Therapy in Patients Undergoing Percutaneous Coronary Intervention

Clinical Trials of Low‐Molecular‐Weight Heparins in Cardiology

Unstable angina and non-ST-segment elevation myocardial infarction

Contact Info

Product

Resources

About